Last modified: 2014-04-03
Abstract
Aim: Oxygen therapy used in the treatment of perinatal hypoxia induce neurodegeneration in babies with immature antioxidant mechanisms. Zonisamide is a new antiepileptic drug used in childhood intractable seizures. Many studies demonstrated its neurprotective effects. There is no study evaluating its effect on hyperoxic brain ınjury. The aim of this study is to investigate the neuroprotective effect of zonisamide on hyperoxia induced neonatal brain injury.
Material and Methods:
A total of 21 Wistar rat pups were used. The animals were divided into three groups: control group, hyperoxia group, and zonisamide-treated group. Wistar rat pups in the hyperoxic groups were exposed to 80% oxygen from birth until postnatal day 5. The hyperoxia + zonisamide group received an intraperitoneal injection of zonisamide. We used TUNEL and active Caspase-3 examination to demonstrate cell death and apoptosis in hippocampus, prefrontal and parietal cortex of neonatal rats which were exposed to hyperoxia.
Results: The number of neurons in hippocampus, prefrontal and parietal cortex significantly decreased in hyperoxia group compared to control group. Zonisamide significantly preserved the number of neurons in CA1 and dentate gyrus parts of hippocampus, prefrontal and parietal cortex. Zonisamide treatment also decreased the number of apototic neurons in all examined parts of hippocampus, prefrontal and parietal cortex.
Conclusion: We suggest that zonisamide treatment may be used as a neuroprotective agent in hyperoxic brain injury.
Keywords
References
[1] O.D. Saugstad, Is oxygen more toxic than currently believed? Pediatrics. 108 (2001) 1203–1205.
[2] T. Hoehn, U. Felderhoff-Mueser, K. Maschewski, C. Stadelmann, M. Sifringer, P. Bittigau, P. Koehne, M. Hoppenz, M. Obladen, C. Bührer, Hyperoxia causes inducible nitric oxide synthase-mediated cellular damage to the immature rat brain, Pediatr Res. 54 (2003) 179–184.
[3] U. Felderhoff-Mueser, P. Bittigau, M. Sifringer, B. Jarosz, E. Korobowicz, L. Mahler, T. Piening, A. Moysich, T. Grune, F. Thor, R. Heumann, C. Bührer, C. Ikonomidou, Oxygen causes cell death in the developing brain, Neurobiol Dis. 17 (2004) 273–282.
[4] H.J. Rozycki, P.G. Comber, T.F. Huff, Cytokines and oxygen radicals after hyperoxia in preterm and term alveolar macrophages, Am J Physiol Lung Cell Mol Physiol. 282 (2002) L1222–1228.
[5] B.T. Pierce, P.G. Napolitano, L.M. Pierce, C.C. Apodaca, R.F. Jr. Hume, B.C. Calhoun, The effects of hypoxia and hyperoxia on fetal-placental vascular tone and inflammatory cytokine production, Am J Obstet Gynecol. 185 (2001) 1068 –1072.
[6] S.M. Allan, N.J. Rothwell, Cytokines and acute neurodegeneration, Nat Rev Neurosci. 2 (2001) 734 –744.
[7] M.Murata, Novel therapeutic effects of the anti-convulsant, zonisamide, on parkinson's disease, Curr.Pharm.Des. 10 (2004) 687–693.
[8] A. Atlı, S. Dogra, Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study, Pain Med. 6 (2005) 225–234.
[9] M.E.Jr. Drake, N.I. Greathouse, J.B. Renner, A.D. Armentbright, Open-label zonisamide for refractory migraine, Clin Neuropharmacol. 27 (2004) 278–280.
[10] M. Murata, E. Horiuchi, I. Kanazawa, Zonisamide has beneficial effects on Parkinson's disease patients, Neurosci.Res. 41 (2001) 397–399.
[11] T.W. Rösler, O. Arias-Carrión, G.U. Höglinger, Zonisamide: aspects in neuroprotection, Exp Neurol. 224 (2010) 336–339.
[12] S.V. Kothare, J. Kaleyias, Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety, Expert Opin Drug Metab Toxicol. 4 (2008) 493–506.
[13] T. Hayakawa, Y. Higuchi, H. Nigami, H. Hattori, Zonisamide reduces hypoxic–ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect, Eur J Pharmacol. 257 ( 1994) 131–136.
[14] A.J. Owen, S. Ijaz, H. Miyashita, T. Wishart, W. Howlett, A. Shuaib, Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study, Brain Res. 770 (1997) 115–122.
[15] A. Mori, Y. Noda, L. Packer, The anticonvulsant zonisamide scavenges free radicals, Epilepsy Res. 30 (1998) 153–158.
[16] M. Komatsu, M. Hiramatsu, L.J. Willmore, Zonisamide reduces the increase in 8-hydroxy-2′-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats, Epilepsia. 41 (2000) 1091–1094.
[17] J. Dobbing, The later growth of the brain and its vulnerability, Pediatrics. 53 (1974) 2–6.
[18] H.J. Romijn, M.A. Hofman, A. Gramsbergen, At what age is the developing cerebral cortex of the rat comparable to that of the full-term newborn human baby? Early Hum Dev. 26 (1991) 61–67.
[19] G. Paxinos, C. Watson, Thr Rat Brain in Stereotaxic Coordinates, 2nd ed., Academic Press, New York, 1986.
[20] U. Felderhoff-Mueser, M. Sifringer, O. Polley, M. Dzietko, B. Leineweber, L. Mahler, M. Baier, P. Bittigau, M. Obladen, C. Ikonomidou, C. Bührer, Caspase-1–Processed Interleukins in Hyperoxia-Induced Cell Death in the Developing Brain, Ann Neurol. 57 (2005) 50–55.
[21] U. Yis, S.H. Kurul, A. Kumral, S. Cilaker, K. Tugyan, S. Genc, O. Yilmaz, Hyper-oxic exposure leads to cell death in the developing brain, Brain Dev. 30 (2008) 556–562.
[22] B. Gerstner, C. Buhrer, C. Rheinlander, O. Polley, A. Schuller, M. Berns, U. Felderhoff Mueser, Maturation-dependent oligodendrocyte apoptosis caused by hyperoxia, J Neurosci Res. 84 (2006) 306–315.
[23] B. Gerstner, T.M. DeSilva, K. Genz, A. Armstrong, F. Brehmer, R.L. Neve, U. Felderhoff Mueser, J.J. Volpe, P.A. Rosenberg, Hyperoxia causes maturation-dependent cell death in the developing white matter, J Neurosci. 28 (2008) 1236–1245.
[24] M. Komatsu, Y. Okamura, M. Hiramatsu, Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats, Neurosciences. 21 (1995) 23–29.
[25] Y. Noda, A. Mori, L. Packer, Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus, Res Commun Mol Pathol Pharmacol. 105 (1999) 23–33.
[26] H. Minato, C. Kikuta, B. Fujitani, Y. Masuda, Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion–reperfusion in rats, Epilepsia. 38 (1997) 975–980.